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Abstract: 
Cost-effectiveness analysis (CEA) plays a key role informing decision-making in healthcare and, 
consequently, the interpretation of its results is discussed in formal guidance from health technology 
assessment (HTA) organisations. A body of research indicates different willingness to pay for more 
effective interventions than willingness to accept less effective interventions, which some suggest 
supports application of different cost-effectiveness thresholds depending on whether an 
intervention is considered more or less effective than the comparator. We review the theoretical 
basis for the use of differential thresholds within HTA organisations, and question whether they are 
compatible with coherent decisions and social values. The National Institute for Health and Care 
Excellence (NICE) is one such organisation, providing recommendations on which healthcare 
interventions to adopt in the United Kingdom. NICE guidance describes the decision rules it employs, 
including comparing CEA results to a cost-effectiveness threshold that defines the boundaries 
beyond which an intervention is no longer considered to provide value for money. Our review of 
NICE guidance finds that it describes a common threshold range for all alternatives, in line with the 
theoretical basis for a supply-side threshold. However, we also find that the guidance focuses on the 
application of the threshold as a decision rule for more effective and more expensive treatments, 
with less guidance provided on less effective and less expensive treatments. We make suggestions 
for how HTA organisations can better support application of decision rules to interventions that are 
less effective and less expensive.  
 
Key points: 
 Guidance on comparing cost-effectiveness results to decision thresholds is often 
applicable only to decisions about more costly and more effective alternatives 
 The need to refer to a decision threshold indicates that both health losses and gains 
will follow regardless of whether a more or less effective alternative is 
recommended 
 Prominent guidance on how population health is improved by releasing resources 
could improve consistency in decision making 
 
Keywords: CﾗゲデどWaaWIデｷ┗WﾐWゲゲ ;ﾐ;ﾉ┞ゲｷゲが ┘ｷﾉﾉｷﾐｪﾐWゲゲ デﾗ ヮ;y, willingness to accept, opportunity cost, 
IﾗゲデどWaaWIデｷ┗WﾐWゲゲ デｴヴWゲｴﾗﾉSゲが ヮヴｷﾗヴｷデ┞ ゲWデデｷﾐｪ 
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1. Introduction 
In many jurisdictions, the decision about whether to endorse an intervention for use in the 
healthcare system is informed by an appraisal process that includes economic evaluation to estimate 
the costs and health consequences from introducing alternative health interventions.  The cost-
effectiveness evidence aims to guide investment to interventions that provide value for money 
(where the benefits outweigh the costs).  Although the majority of appraisals inform decisions about 
whether to recommend new and more costly interventions, there is potential to add value by 
informing decisions that recommend less effective but also less costly interventions that free up 
resources for other purposes.   
 
This paper considers whether formal Health Technology Appraisal (HTA) and guideline processes 
work for both new and existing interventions.  We examine how well decision-making committees 
are supported in making consistent recommendations concerning the adoption of more versus less 
effective interventions.  We use as an exemplar the National Institute for Health and Care Excellence 
(NICE), which makes recommendations intended to direct health spending in the United Kingdom 
(UK) [1].  
 
There are examples of decision-making committees applying different rules to existing drugs versus 
new drugs.  This may imply that they consider the trade-off between increased cost for increased 
effect on a different basis to reduced cost for reduced effect [2]. In 2016 pirfenidone was part of 
NHS practice following a recommendation by NICE in 2013 to treat idiopathic pulmonary fibrosis 
sufferers with 50%-80% forced vital capacity (a patient population with moderate disease).  During 
reappraisal the ICER was found to range between £25,700 or £28,900 per quality adjusted life year 
(QALY) gained compared to best supportive care in patients with 50%-80% forced vital capacity, and 
was similar for patients with 80%-90% forced vital capacity (a mild patient population) [3].  Although 
the ICERs in mild and moderate patients were comparable, the appraisal committee chose to 
maintain the previous recommendation in the moderate group without extending it to the mild 
subgroup.  In the appeals that followed, it was noted that: 
 
さTｴW CﾗﾏﾏｷデデWW chose not to reverse the recommendation for the 50-80% group ぐく because 
it felt that this would be unfairざ[4] 
 
さTｴW IﾗﾏﾏｷデデWW デﾗﾗﾆ ; ┗ｷW┘ デｴ;デ ｷデ ┘;ゲ not cost effective in mild or moderate disease. The 
committee did not find the drug cost effective in the whole population, but it chose not to 
take away a treatment from patients with moderate disease because the NHS currently 
offers pirfenidone, so the NHS would have to disinvest and that is something that the 
IﾗﾏﾏｷデデWW IｴﾗゲW ﾐﾗデ デﾗ Sﾗくざ [5]  
 
The issue ﾗa けa;ｷヴﾐWゲゲげ ヴWヮヴWゲWﾐデゲ ; ┗;ﾉ┌W ﾃ┌SｪWﾏWﾐデ デｴ;デ removing access to existing interventions 
warrants different consideration to providing access to previously unavailable interventions.  This 
paper considers the role of such a value judgement in the methods and processes of HTA.  Section 
two outlines the principles of cost-effectiveness analysis.  Section three provides an overview of the 
documentation that guides NICE decision-making committees in making recommendations.  Section 
four discusses how cost-effectiveness analysis informs recommendations in the NICE decision-
making context, and considers the implications of applying different values to health losses 
compared to health gains.  
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2. Losses, gains and the cost-effectiveness plane 
Cost-effectiveness evidence includes the difference between an intervention and a comparator in 
terms of incremental costs and incremental effects. Decision making committees who determine 
recommendations are typically presented with cost-effectiveness results in terms of the incremental 
cost-effectiveness ratio (ICER), which is the difference in mean incremental cost divided by the 
difference in mean incremental health gains, usually in terms of quality adjusted life years (QALYs).  
The incremental costs and effects do not show the extent of gains and losses to each individual, but 
rather the mean impact in the group of patients that would be subject to the recommendation [6].  
The range of experiences from which those averages are calculated can be comprised of individual 
gains and losses. 
 
This information can be depicted as a point on the incremental cost-effectiveness plane (Figure 1).  
This plane includes four quadrants, with incremental cost shown on the y-axis and incremental 
effects on the x-axis, with the origin representing the comparator intervention. The value of 
interventions that appear in the North-West (more costly, less effective) and South-East (more 
effective, less costly) quadrants is apparent without recourse to any cost-effectiveness threshold.  
When interventions appear in the North-East or South-West quadrants, there is a trade-off between 
costs and effects, and a cost per QALY threshold can define the accepted rate of exchange [6].   
 
The recommendation of an intervention imposing greater costs on the healthcare sector than 
existing service provision requires, in the context of a fully allocated fixed budget, that service 
providers reduce provision of existing activities to release the required resources [6].  It represents 
an investment to generate health gains among individuals treated with that intervention, at the 
expense of disinvestment in other activities that could have produced health benefits for other 
individuals.  The recommendation of an intervention that is less costly compared with existing 
service provision releases resources that can be invested in other health interventions.  This 
recommendation can be reframed as the recommendation to cease a specific activity that is more 
costly and more effective.  The term disinvestment is used to describe a decision to discontinue 
funding for an intervention currently provided within the healthcare system [7].   
  
 
Figure 1. The cost-effectiveness plane 
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2.1 Framing the decision problem 
With a common cost per QALY threshold in the North-East and South-West quadrants, the framing 
in terms of which is labelled the けinterventionげ and which is labelled the けcomparatorげ is 
inconsequential.  However, if different decision rules (cost-effectiveness thresholds), apply in these 
quadrants the designation of けinterventionげ and けcomparatorげ is important.  
 
When pirfenidone was chosen through the topic selection process, best supportive care (BSC) was 
identified as a relevant comparator. BSC was represented at the origin of the incremental cost-
effectiveness plane, and the incremental costs and effects for pirfenidone versus BSC were located 
in the North-East quadrant of the plane (ICER £24,000 per QALY gained) [8]. NICE does not define a 
maximum acceptable ICER, but does indicate that below £20,000 per QALY gained, the intervention 
would be regarded as cost-effective [9, 10]. A threshold of £20,000 per QALY indicates that 
discontinuing funding from existing activities would result in health losses at a rate of one QALY per 
£20,000. Transferring those funds to pirfenidone would provide 0.83 QALYs per £20,000, resulting in 
a loss of 0.17 QALYs per £20,000 spent.  
 
If, in the review process, BSC is appraised as the intervention and with pirfenidone labelled as a 
comparator, the economic evaluation would estimate an ICER for BSC compared with pirfenidone. 
As BSC is less costly and less effective than pirfenidone, it would fall in the South-West quadrant 
(ICER £24,000 saved per QALY lost). The principles of cost-effectiveness analysis indicate that less 
costly and less effective interventions should be recommended if the ICER is greater than the 
decision threshold, in this case £20,000 per QALY. This would ensure that technologies are 
recommended if they save more than £20,000 per QALY lost. For every £24,000 no longer spent on 
pirfenidone, there would be one fewer QALY spread among idiopathic pulmonary fibrosis sufferers, 
but 1.2 QALYs more across all patients served by the NHS, resulting in a gain of 0.2 QALYs per 
£24,000 spent. The principle is that the reduction in costs from recommending BSC would translate 
into more QALYs through investment in other activities than would continued investment in 
pirfenidone. 
 
The notion of being less or more effective is relative, so how is the presentation determined? 
Identifying one intervention as current practice can provide a reference point from which to judge 
relative effect. Labelling interventions as current, けﾐW┘げ ﾗヴ けﾗﾉSげ is problematic when current practice 
is composed of multiple interventions. For example, pirfenidone was represented in the North-East 
quadrant even when it was reappraised and represented at least a component of current NHS 
practice. In the presence of more than two alternatives, options are commonly ranked by their mean 
effects, or costs. Then, the least effective, or expensive, option is represented on the origin of the 
cost-effectiveness plane. In such cases only the North East quadrant of the cost-effectiveness plane 
is used.  
 
2.2 Investment and disinvestment due to NICE recommendations 
NICE makes decisions that affect the availability and delivery of health interventions for future 
individuals, without altering the entitlement of patients who are currently in receipt of an 
ｷﾐデWヴ┗Wﾐデｷﾗﾐ ふけWﾐSﾗ┘WSげ ┘ｷデｴ デヴW;デﾏWﾐデぶく けLﾗゲゲげ ﾗa ｴW;ﾉデｴ ｷゲ ｷﾐ デWヴﾏゲ ﾗa Iﾗﾏヮaring possible future 
resource allocations, and no patients are subject to interventions that reduce their quality adjusted 
life expectancy. In the case of pirfenidone, a decision not to recommend it would not affect the 
ability to continue its use in patients already receiving the drug, but would inhibit its use in future 
patients with the same indication.   
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Where NICE compares mutually exclusive alternatives, the recommendation of a new intervention 
can result in disinvestment of current care, unless the new intervention is adjunct or sequential to 
usual care. Recommending an intervention under the multiple technology appraisal process implies 
the discontinuation of the alternatives, at least for future patients. Under the single technology 
appraisal process, a recommended intervention becomes an option alongside existing alternatives, 
albeit one that patients can oblige the NHS to fund. Under the guidelines process, recommendations 
do not carry any legal mandate. Overall, a recommendation to use an intervention cannot 
necessarily be interpreted as an instruction to cease the availability of the alternatives. 
In the appraisal process, the activities to be displaced following the recommendation of more costly 
interventions are unspecified. Returning to Figure 1, in the North-East quadrant the positive 
incremental costs represent an expected loss of health for unidentified groups, and incremental 
effects represent a gain in expected health among those eligible for treatment with the 
recommended intervention. In the South-West quadrant, the negative incremental costs represent a 
gain in expected health benefits for unidentified groups, and negative incremental effects represent 
a loss in expected health benefits among those eligible for treatment with the recommended 
intervention.  
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3. The foundations of the NICE guidance process 
The decision-making committees in charge of recommendations comprise a multidisciplinary 
mixture of experts not limited to health economists. NICE documentation, including methods and 
process guides, act as an important reference point for understanding economic evaluation. Social 
value judgements are an inevitable feature of the NICE guidance process, and NICE has produced a 
document summarising the principles adopted when making decisions about cost-effectiveness. We 
reviewed the NICE manual (used for developing NICE guidelines), the guide to the methods of 
technology appraisal (which informs the technology appraisal process), and NICE Social Value 
Judgements document for references on the recommendation of less effective and less costly 
alternatives [9-11].   
 
3.1 NICE process and methods guidance 
The manual for developing NICE guidelines clearly states that guidance committees  
さshould be encouraged to consider recommendations that increase effectiveness at an acceptable 
level of increased cost or; are less effective than current practice, but free up sufficient resources that 
can be re┽invested in public sector care or services to increase the welfare of the population receiving 
careざく [10]   
 
The guide to the methods for technology appraisal states that NICE must take account of the overall 
resources available to the NHS, and highlights that decisions on the cost-effectiveness of an 
intervention must include judgements on the implications for healthcare programmes for other 
patient groups that may be displaced because of the new intervention. 
 
The NICE process and methods guides stress the importance of consistency between appraisals, 
including in the judgements committees make regarding the cost-effective use of NHS resources.  
Committees are guided not to give particular priority to interventions that are part of current 
practice. 
 
 さIﾐ ;ﾐ┞ ゲｷデ┌;デｷﾗﾐ ┘ｴWヴW ろI┌ヴヴWﾐデ ヮヴ;IデｷIWろが Iﾗﾏヮ;ヴWS ┘ｷデｴ ;ﾐ ;ﾉデWヴﾐ;デｷ┗W ;ヮヮヴﾗ;Iｴが 
generates an ICER above a level that would normally be considered cost-effective, 
the case for continuing to invest in it should be carefully considered, based on similar 
ﾉW┗Wﾉゲ ﾗa W┗ｷSWﾐIW ;ﾐS IﾗﾐゲｷSWヴ;デｷﾗﾐゲ デｴ;デ ┘ﾗ┌ﾉS ;ヮヮﾉ┞ デﾗ ;ﾐ ｷﾐ┗WゲデﾏWﾐデ SWIｷゲｷﾗﾐくざ  
[10] 
 
Despite these explicit acknowledgements of recommendations of less costly and less effective 
interventions, our review found that throughout the guidance documents the descriptions of how 
the ICER is used to determine cost-effectiveness is mostly framed in terms of cost per QALY gained 
(the North-East quadrant of figure 1). 
 
3.2 The NICE cost per QALY threshold 
The decision-making context for NICE recommendations is the allocation of public resources, the 
extent of which are determined outside of NICE control. The NICE manual instructs committees to 
consider whether an intervention is consuming more resources than its value is contributing based 
on NICE's cost per QALY threshold. The NICE technology appraisal guidance states that given the 
fixed budget of the NHS, the appropriate maximum acceptable ICER is determined by the 
opportunity cost of programmes displaced by new, more costly technologies. NICE does not define a 
maximum acceptable ICER, but indicates a range between £20,000 and £30,000 per QALY gained.   
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The nuance of how the application of a decision rule to compare an ICER against a threshold differs 
in the South-West quadrant is not explicitly acknowledged within the NICE methods and process 
guides. In the South-West quadrant the threshold is a representation of the minimum acceptable 
ICER (the minimum amount of cost savings required to generate more value than the loss of health 
benefits compared to the more effective alternative). Guiding committee members to recommend 
interventions with ICERs greater than this threshold may reinforce the intention to free up resources 
where they can be re-invested to increase welfare. 
 
3.3 NICE Social Value Judgements 
What principles underlie the use of cost-effectiveness evidence by the HTA body? NICE subscribes to 
four moral principles (respect for autonomy; non-maleficence; beneficence; distributive justice) and 
the accompanying guidance notes that treatments that have adverse consequences should provide 
benefits that balance these harms. NICE Social Value Judgements highlights four (out of eight) 
principles in the chapter on evidence-based decision-making. Principles 2 to 4 relate to cost-
effectiveness. Principle two states that committees must consider cost-effectiveness in making 
recommendations. Principle three notes that decisions should not only be based on relative costs 
and effects but also reflect the need to distribute health resources fairly within society. Principle four 
describes how committees should interpret ICERs based on cost per QALY. It notes that NICE should 
explain its reasons when it decides that an intervention with an ICER below £20,000 per QALY gained 
is not cost-effective, and when it decides that an intervention with an ICER above £20,000-£30,000 
per QALY gained is cost-effective. Principle five describes how NICE reconciles respect for autonomy 
and individual choice against the interests of users of the NHS as a whole. It states that the 
expectation of individual NHS users to receive treatments to which their condition will respond does 
not impose a requirement on committees to recommend interventions that are not cost-effective.  
 
Broadly, the social value judgements make clear that fairness should be assessed with reference to a 
balance between benefits and harms, and in terms of impacts on all NHS users as a whole. Given 
that NICE informs the allocation of a fixed pot of NHS resources, the NICE cost per QALY threshold 
does not require committees to decide how much an additional QALY is worth, but simply how many 
QALYs the NHS can produce with the resources demanded by alternative interventions. 
Consequently, NICE Social Value Judgements do not, and do not need to, include comments on the 
societal value to attach to an additional QALY.  
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4. Theoretical foundations for differential treatment of losses and gains 
Here, we briefly review how previous researchers have investigated whether people treat losses 
differently to gains and what are the potential implications for health technology assessment [12]. 
 
In cost-effectiveness analysis and in NICE guidance, the decision rule variably refers to a cost per 
QALY threshold, opportunity costs, and a maximum acceptable ICER. The derivation and 
interpretation of cost per QALY thresholds and the determination of a maximum acceptable ICER can 
differ markedly according to the decision-making context. Decision-making committee members 
may benefit from greater support to understand these terms and why some interpretations should 
not have bearing on their recommendations. TｴW H;ゲｷゲ aﾗヴ NICEげゲ Iﾗゲデ ヮWヴ QALY デｴヴWゲｴﾗﾉS is 
discussed in detail in the literature, and we briefly review the economic concepts they reference in 
support of how this threshold should be interpreted in the NICE decision-making context.   
 
4.1 Opportunity cost 
The decision to invest in a particular good removes an opportunity to use the resources invested to 
purchase other desirable goods. When NICE appraises interventions from a health sector 
perspective, opportunity cost is in terms of the restricted set of alternative investments that fall 
within the remit of the health sector. There has been a question as to how well the NICE cost per 
QALY threshold reflects opportunity cost [13, 14]. Inconsistency can arise if the basis for the NICE 
cost per QALY threshold departs from the opportunity cost determined by the fixed NHS budget.   
 
4.2 Maximum prices, willingness to pay and maximum acceptable ICERs 
For an individual, the willingness to pay (WTP) for healthcare refers to the maximum that individual 
could pay without reducing their utility (overall satisfaction). It represents the maximum price at 
which the individual would buy the healthcare intervention. Willingness to accept (WTA) refers to 
the amount of compensation the individual would require to maintain their utility following the loss 
of a good (it represents the minimum price at which an individual would sell the good). The 
appropriateness of using WTA instead of WTP depends on whether individuals currently have the 
good in question or have a legal entitlement to it [15]. 
 
For society, the WTP for healthcare represents the maximum that society would be willing to forgo 
in non-healthcare or private consumption to obtain that healthcare [16, 17]. For example, the 
societal WTP for health could be used to inform decisions that determine the size of the NHS budget.  
Although the terms WTP and cost-effectiveness threshold has been used interchangeably in the 
past, differences arise if the size of the budget does not correspond with societal WTP for health 
gains [18]. The cost per QALY threshold should represent the opportunity costs of the decision, 
which are the WaaWIデゲ ﾗﾐ ヮ;デｷWﾐデゲげ ｴW;ﾉデｴ S┌W to a marginal change in expenditure given a fixed 
budget. The maximum acceptable ICER indicates the cost per QALY gained from those programmes 
that would be discontinued to release funds for other activities.   
 
4.3. Differential treatment of losses and gains 
Many studies find that WTA exceeds WTP for the same good, but there is a lack of consensus as to 
whether the difference is meaningful, and the magnitude of the difference [19-28]. Competing 
explanations for why the discrepancy might reflect a true difference in value include loss aversion 
and the endowment effect, status quo bias, and the substitution effect [29, 30]. Section 4.2 showed 
that the notion of WTP should not apply within the NICE decision-making context. However, this 
discrepancy between valuing health losses versus health gains could potentially influence committee 
members in forming recommendations.   
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4.3.1 Differential treatment of losses and gains from the demand side 
For decision-making contexts where the budget is not fixed, one might value health gains in terms of 
WTP and health losses in terms of WTA. Recalling the comparison of pirfenidone (P) to BSC, 
recommendation of the more costly intervention pirfenidone leads to a loss of health from 
alternative health improving interventions. This means that additional costs (CP に CBSC) should be 
valued using WTA, and compared with the health gains (QP に QBSC) valued using WTP. If we say that 
WTA is simply WTP multiplied by the ratio of WTA to WTP (WTA:WTP), we can weight health losses 
by this ratio in calculating the ICER.1 The decision rule for a more costly intervention such as 
pirfenidone can be written as in Equation (1). 
 
(1)   
岫寵鍋貸寵遁縄頓岻軟畷豚軟畷鍋岫町鍋貸町遁縄頓岻 隼 兼欠捲件兼憲兼 荊系継迎 
 
We rearrange the decision rule in Equation (1) to show the ICER for pirfenidone versus BSC against a 
maximum ICER or cost per QALY threshold weighted by WTA:WTP. Equation (2) applies to 
recommendations for interventions depicted in the North-East quadrant of the incremental cost-
effectiveness plane: 
 
 
(2)   
岫寵鍋貸寵遁縄頓岻岫町鍋貸町遁縄頓岻 隼 兼欠捲件兼憲兼 荊系継迎 閥 調脹凋調脹牒 
 
Recommendation of less costly interventions leads to expected health gains through the release of 
resources to provide other health improving interventions. This means that cost savings should be 
valued using WTP, and compared with health losses valued using WTA. Equation (3) shows the 
decision rule for BSC, where the health losses are weighted using the ratio of WTA:WTP. Equation (4) 
rearranges this in terms of an intervention that is depicted in the South-West quadrant of the 
incremental cost-effectiveness plane: 
 
(3)   
岫寵遁縄頓貸寵鍋岻岫町遁縄頓貸町鍋岻軟畷豚軟畷鍋 伴 兼欠捲件兼憲兼 荊系継迎 
 
(4)   
岫寵遁縄頓貸寵鍋岻岫町遁縄頓貸町鍋岻 伴 兼欠捲件兼憲兼 荊系継迎┻ 調脹凋調脹牒 
 
Equations (2) and (4) reveal how a discrepancy between WTA and WTP leads to the use of different 
thresholds in the North-East and South-West quadrants. The maximum acceptable ICER is multiplied 
by the ratio of WTP:WTA in the North-East quadrant, and the ratio of WTA:WTP in the South-West 
quadrant.   
 
4.3.2 The implications of kinked thresholds 
Figure 2 compares a kinked decision threshold (line A0B), assuming a WTA to WTP ratio of 2:1, with 
a single threshold, assuming a maximum acceptable ICER of £20,000 per QALY (line C0D). Based on 
these assumptions, equation (4) implies that the decision threshold would be to recommend 
technologies with ICERs above £40,000 saved per QALY lost in the South-West quadrant. Equation 
(2) indicates that the decision rule would be to recommend technologies with ICERs under £10,000 
per QALY gained in the North-East quadrant. More effective and more costly technologies with ICERs 
                                                          
1 This equally applies if the cost-effectiveness results are presented using the net monetary benefit (NMB) or net health 
benefit (NHB). The calculation of the NMB and NHB relies on the conversion of health benefits into monetary terms, or 
costs into health benefit equivalent, i.e. on the rate of exchange between costs and health outcomes.6. Drummond MF, 
Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes: 
Oxford university press; 2015. 
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in the range £11,000 to £20,000 would improve net health, but would not be recommended. Less 
effective and less costly technologies with ICERs in the range £20,000 to £39,000 saved per QALY lost 
would improve net health, but would not be recommended. A technology that was recommended 
with an ICER below £10,000 per QALY would have to be re-appraised at an ICER above £40,000 per 
QALY before the recommendation would be reversed.   
 
 
Figure 2. Kinked threshold 
 
A kinked threshold leads to a status quo bias, where the current treatment is compared with a more 
permissive threshold (e.g. £40,000 per QALY) than the one used for new programmes (e.g. £10,000 
per QALY). While the current patients will receive the already funded treatment, this will not be 
necessarily true for future patients who could benefit as much or even more from new treatments.  
This introduces an inconsistency in how health is valued between current and future patients [13, 
31]. 
 
An additional issue with a kinked threshold would be the time ordering of the decision. In this 
respect, applying different values to increased costs compared with reduced costs means that the 
decision will differ depending on the chronological order in which treatments are appraised. This has 
implications for NICE processes and review of previous recommendations. Following a decision to 
approve a costlier and more effective intervention like pirfenidone for use in the NHS, it becomes 
the new current practice. In light of new evidence, and without the arrival of new comparators, the 
review compares the less effective and less costly BSC against this new current practice. Unless new 
evidence suggests that pirfenidone is less expensive than BSC, the threshold that the ICER for BSC 
compared with pirfenidone would have to exceed would be higher than that applied in the initial 
appraisal. In general, this could create sclerosis in the system in favour of the comparator selected to 
represent the origin of the cost-effectiveness plane.       
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4.4 Differential treatment of losses and gains from the supply side  
Existing interventions are displaced or contracted to release resources when a more costly 
intervention is recommended. This set of displaced interventions differ to the programmes that 
would be introduced or expanded when funds are released following the recommendation of less 
expensive intervention [32]. Diminishing marginal returns indicates that as you expand budgets, the 
amount of health gained from each additional pound spend will fall.  This could be represented by a 
kinked threshold.  
 
Lomas et al. attempted to estimate the average change in health observed consequent to decisions 
that accompany either the contraction or the expansion of a healthcare budget [33]. For the NHS, it 
was empirically determined that expanding expenditure by 3% might provide one additional QALY 
per £13,464 invested, but that contracting expenditure by 2% would remove interventions that were 
generating one QALY per £12,047 invested [33]. Based on these estimates, the curvature in the 
supply side of the threshold would be relatively small. Eckerman and Pekarsky took an alternative 
view that compared the optimal programme for expansion to the optimal programme for 
contraction [34]. The kink in the supply side of the threshold proposed by Eckerman and Pekarsky is 
substantially larger than the one observed in the empirical study conducted by Lomas et al [35]. 
Eckerman and Pekarsky assume that resources obtained from recommending less costly and less 
effective alternatives would be reallocated to the most cost-effective funded technology, while the 
funds for more costly alternatives are obtained by disinvesting from the least cost-effective 
technology. This assumption does not appear to be reflected in the observed data, nor reflect the 
HTA process where NICE does not direct the resource reallocation required to support its 
recommendations. 
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5. Discussion 
This paper summarises the foundations of using cost-effectiveness evidence in health technology 
assessment and examined the consequences of differential treatment of losses and gains in 
healthcare. 
 
Whilst decision-making in healthcare is not merely concerned with cost-effectiveness, formal HTA 
processes employing cost-effectiveness thresholds to define value for money still play an important 
role in resource allocation. However, much of the process and application of HTA tools has focussed 
on decision rules in the case of more effective and more expensive technologies, and describing the 
social value judgments that mitigate these rules [10, 11]. On the contrary, the decision rules in 
evaluating programmes able to free up resources に albeit at the cost of reduced effectiveness に are 
described in less detail. Guidance committees are asked to make consistent judgements across 
interventions. There is clear evidence for biases in individual decision-making favouring identified 
patients over the unidentified patients who bear the opportunity cost if additional resources are 
required for an intervention. Similarly, individuals ascribe a greater value to a loss compared with a 
gain of an equivalent amount. 
 
Based on the current NICE manuals, the same threshold should be applied regardless of whether the 
ICER is presented in the North-East or the South-West quadrant of the incremental cost-
effectiveness plane. However, the appraisal of currently funded technologies, such as the reappraisal 
of pirfenidone, have suggested otherwise. By better elucidating how cost-effectiveness analysis 
justifies the adoption of a less effective technology which would release sufficient resources to be 
reinvested in programmes that offset the health loss, existing NICE processes and manuals could 
potentially do more to prevent committee members inadvertently applying psychological bias in 
forming recommendations. 
 
Differential treatment of losses and gains could provide a possible explanation for incongruence in 
the decision rule applied to the North-East and South-West quadrants. Although WTA the loss of a 
currently provided service might exceed WTP for the same service at the individual level, there is 
limited evidence as to whether this discrepancy manifests at a societal level [12, 20, 22]. However, 
the decision context and the cost-effectiveness threshold applied in HTA bodies such as NICE is not 
the societal WTP for healthcare (although this societal value may inform the budgets within which 
they operate). Where decision bodies such as NICE do not control the size of the healthcare budget, 
any discrepancy between societal WTA and WTP for health should not affect their decisions. HTA 
processes operating in settings without fixed healthcare budgets may issue recommendations that 
control how the resources are deployed between health and other sectors.   
 
Limited attention has been paid to the fact that health gains and losses occur as a consequence of all 
NICE recommendations. For example, we found little in the NICE manuals and social value 
judgements to make explicit the fact that disinvestment from existing, health improving activities 
will occur because of recommendations for more costly interventions.    
  
The existing literature provides extensive support for why a demand-side interpretation of the cost-
effectiveness threshold is irrelevant in the decision-making context of a body such as NICE. This 
supports the use of a single decision-making threshold. Some have explored whether there is 
support for a different decision rule for North-East versus South-West quadrants from a supply side 
interpretation of the cost-effectiveness threshold. The cost of generating a unit of healthcare 
through the alternative activities forgone because of any recommendation will differ between cost 
increasing versus cost saving activities. The empirical evidence on the diminishing marginal returns 
of health expenditure suggests that if there is any discrepancy it might be negligible.  For example, 
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the impact of pirfenidone on the total healthcare expenditure in 2016 was 0.014% [36, 37], which is 
much smaller than the budget expansion (3%) or contraction (2%) required to produce a kink of 
around £1,500 in the threshold [33]. 
 
A consequence of adopting a different decision rule for assessing a more costly intervention 
compared with ceasing to provide the same intervention is that the temporal ordering of decisions 
affects the recommendations. Allowing for a kinked threshold would lead to differential 
consequences for future patients, which implies a different weighting of current patients over future 
patients [31]. When HTA compares the average change in cost divided by the average change in 
health provided by a new programme against a threshold, it is in pursuit of improving society-wide 
health. Applying a kinked threshold that goes beyond any difference in opportunity costs for cost 
saving as opposed to cost increasing technologies, appears in contrast with making coherent 
decisions and, therefore, it would pose important normative and ethical questions.   
 
The deployment of a health programme will inevitably result in health losses, either directly or 
indirectly. When a more effective and more costly intervention is appraised, this loss is indirectly 
captured by the threshold, which represents the alternative use of the forgone resources. The health 
loss due to a less effective and less expensive intervention, on the other hand, is directly captured by 
the reduction in population health. The NICE documentation shed light on the importance of 
balancing these health losses, ultimately improving population health, setting the cost-effectiveness 
boundaries for the North-East technologies. Future guidelines have the opportunity to review the 
current process and, thereby, to make more prominent that the assessment of South-West 
technologies does not differ from the North-East one since they both impose health losses.  
  
Does HTA guidance give adequate consideration to decisions about less costly and less effective alternatives?  13 
 
 
References 
1. National Institute for Health and Care Excellence. Mission statement. 2019  [cited 2019 
18/06/19]; Available from: https://www.nice.org.uk/about 
2. Garner S, Littlejohns P. Disinvestment from low value clinical interventions: NICEly done? 
BMJ 2011;343:d4519. 
3. National Institute for Health and Care Excellence. Final appraisal determination Pirfenidone 
for treating idiopathic pulmonary fibrosis (review of TA282) [ID837] 2016  [cited 2019 28/06/19]; 
Available from: https://www.nice.org.uk/guidance/ta504/documents/final-appraisal-determination-
document-2 
4. National Institute for Health and Care Excellence. Single technology appraisal appeal 
hearing. Advice on pirfenidone for treating idiopathic pulmonary fibrosis (review of TA282) [ID837] - 
appeal decision letter 1. 2016  [cited 2019 28/06/19]; Available from: 
https://www.nice.org.uk/guidance/ta504/documents/appeal-decision 
5. National Institute for Health and Care Excellence. Single technology appraisal appeal 
hearing. Advice on pirfenidone for treating idiopathic pulmonary fibrosis (review of TA282) [ID837] - 
appeal decision letter 2. 2016  [cited 2019 28/06/19]; Available from: 
https://www.nice.org.uk/guidance/ta504/documents/appeal-decision-2 
6. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the 
economic evaluation of health care programmes: Oxford university press; 2015. 
7. National Institute for Health and Care Excellence. NICE Do not Do prompts.2019. 
8. National Institute For Health and Care Excellence. Pirfenidone for treating idiopathic 
pulmonary fibrosis. [TA282]: National Institute for Health and Clinical 
Excellence.; 2013. 
9. National Institute for Health and Care Excellence. Guide to the methods of technology 
appraisal  4 April 2013. 
10. National Institute for Health and Care Excellence. Developing NICE guidelines: the manual: 
National Institute for Health and Care Excellence; 2014 31 October 2014. 
11. National Institute for Health and Care Excellence. Social Value Judgements: Principles for the 
Development of NICE Guidance: National Institute for Health and Care Excellence, 2008 July 2008. 
12. Tunçel T, Hammitt JK. A new meta-analysis on the WTP/WTA disparity. Journal of 
Environmental Economics and Management 2014;68(1):175-87. 
13. Claxton K, Sculpher M, Palmer S, Culyer AJ. Causes for concern: is NICE failing to uphold its 
responsibilities to all NHS patients? Health Economics 2015;24(1):1-7. 
14. Dillon A. Carrying NICE over the threshold. NICE; 2015. 
15. C;ヴゲﾗﾐ ‘Tく CﾗﾐデｷﾐｪWﾐデ V;ﾉ┌;デｷﾗﾐぎ A UゲWヴげゲ G┌ｷSWく Environ Sci Technol. 2000;34:1413r8. 
16. Sugden R, Williams A. The principles of practical cost-benefit analysis. Oxford University 
Press Catalogue. 1978. 
17. Arrow KJ. A difficulty in the concept of social welfare. Journal of Political Economy. 
1950;58(4):328-46. 
18. McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what 
that means. Pharmacoeconomics 2008;26(9):733-44. 
19. Sugden R. Anomalies and stated preference techniques: a framework for a discussion of 
coping strategies. Environmental and Resource Economics 2005;32(1):1-12. 
20. Horowitz JK, McConnell KE. A review of WTA/WTP studies. Journal of environmental 
economics and Management 2002;44(3):426-47. 
21. Shogren JF, Shin SY, Hayes DJ, Kliebenstein JB. Resolving differences in willingness to pay and 
willingness to accept. The American Economic Review 1994:255-70. 
22. Whynes DK, Sach TH. WTP and WTA: do people think differently? Social Science & Medicine. 
2007;65(5):946-57. 
14  CHE Research Paper 175 
 
23. Morrison GC. Willingness to pay and willingness to accept: some evidence of an endowment 
effect. Applied Economics 1997;29(4):411-7. 
24. Martín-Fernández J, Ariza-Cardiel G, Peña-Longobardo LM, Polentinos-Castro E, Oliva-
Moreno J, Gil-L;Iヴ┌┣ AIが Wデ ;ﾉく さG;ｷﾐｷﾐｪ ﾗヴ ﾉﾗゲｷﾐｪざぎ TｴW ｷﾏヮﾗヴデ;ﾐIW ﾗa デｴW ヮWヴゲヮWIデｷ┗W ｷﾐ primary care 
health services valuation. PloS One. 2017;12(12):e0188969. 
25. O'brien BJ, Goeree R, Gafni A, Torrance GW, Pauly MV, Erder H, et al. Assessing the value of 
a new pharmaceutical: a feasibility study of contingent valuation in managed care. Medical Care. 
1998:370-84. 
26. Gヴ┌デデWヴゲ JPが KWゲゲWﾉゲ AGが DｷヴﾆゲWﾐ CDが V;ﾐ HWﾉ┗ﾗﾗヴデどPﾗゲデ┌ﾉ;ヴデ Dが AﾐデW┌ﾐｷゲ LJが JﾗﾗヴW MAく 
Willingness to accept versus willingness to pay in a discrete choice experiment. Value in Health. 
2008;11(7):1110-9. 
27. Knetsch JL, Sinden JA. Willingness to pay and compensation demanded: Experimental 
evidence of an unexpected disparity in measures of value. The Quarterly Journal of Economics. 
1984;99(3):507-21. 
28. O'Brien BJ, Gertsen K, Willan AR, Faulkner A. Is there a kink in consumers' threshold value for 
IﾗゲデどWaaWIデｷ┗WﾐWゲゲ ｷﾐ ｴW;ﾉデｴ I;ヴWい Health Economics 2002;11(2):175-80. 
29. Kahneman D, Knetsch JL, Thaler RH. Anomalies: The endowment effect, loss aversion, and 
status quo bias. Journal of Economic Perspectives. 1991;5(1):193-206. 
30. Hanemann WM. Willingness to Pay and Willingness to Accept: How Much Can They Differ? 
The American Economic Review. 1991;81(3):635-47. 
31. Dﾗ┘ｷW Jく Wｴ┞ IﾗゲデどWaaWIデｷ┗WﾐWゲゲ ゲｴﾗ┌ﾉS デヴ┌ﾏヮ ふIﾉｷﾐｷI;ﾉぶ WaaWIデｷ┗WﾐWゲゲぎ デｴW WデｴｷI;ﾉ WIﾗﾐﾗﾏｷIゲ 
of the South West quadrant. Health Economics. 2004;13(5):453-9. 
32. Culyer AJ. Cost-effectiveness thresholds in health care: a bookshelf guide to their meaning 
and use. Health Economics, Policy and Law. 2016;11(4):415-32. 
33. Lomas J, Claxton K, Martin S, Soares M. Resolving the "Cost-Effective but Unaffordable" 
Paradox: Estimating the Health Opportunity Costs of Nonmarginal Budget Impacts. Value Health. 
2018 Mar;21(3):266-75. 
34. Eckermann S, Pekarsky B. Can the Real Opportunity Cost Stand Up: Displaced Services, the 
Straw Man Outside the Room. Pharmacoeconomics 2014 April 01;32(4):319-25. 
35. Paulden M, McCabe C, Karnon J. Achieving Allocative Efficiency in Healthcare: Nice in 
Theory, not so NICE in Practice? Pharmacoeconomics 2014 April 01;32(4):315-8. 
36. Harker R. NHS Funding and Expenditure 2017. 
37. National Institute for Health and Care Excellence. Single Technology Appraisal. Pirfenidone 
for treating idiopathic pulmonary fibrosis (review of TA282) [ID837] Committee Papers. 
 
